BridgeMD
Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)
EU CTIS ID: 2025-523065-16-00
What this study is testing
To demonstrate that a tailored prescription of antiplatelet drugs can cut the rate of 12-month major cardiovascular events compared to usual care
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Aged ≥18 years old
- Males and females
- Non-cardioembolic ischemic stroke within the previous 14 days
- Starting/prosecuting secondary prevention with single or double anti-platelet therapy after the index stroke
- Written informed consent (informed consent can be obtained on incapacitated patients in accordance with national legislation (versions “ex art. 82” of informed consent to study participation and data treatment consent)
You likely can't join if
- Known hypersensitivity to aspirin, clopidogrel or ticlopidine, or to any of the excipient.
- Severe renal impairment.
- Uncontrolled severe cardiac failure.
- Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis.
- Concurrent need for anticoagulation for any indication.
- Contraindication to study drugs.
See the full eligibility criteria
- Aged ≥18 years old
- Males and females
- Non-cardioembolic ischemic stroke within the previous 14 days
- Starting/prosecuting secondary prevention with single or double anti-platelet therapy after the index stroke
- Written informed consent (informed consent can be obtained on incapacitated patients in accordance with national legislation (versions “ex art. 82” of informed consent to study participation and data treatment consent)
- Known hypersensitivity to aspirin, clopidogrel or ticlopidine, or to any of the excipient.
- Severe renal impairment.
- Uncontrolled severe cardiac failure.
- Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis.
- Concurrent need for anticoagulation for any indication.
- Contraindication to study drugs.
- Indications to perform carotid revascularization surgery.
- Pregnancy and breastfeeding; WOCBP not using acceptable contraception during the trial period (combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion. vasectomised partner, sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide).
- History of asthma induced by the administration of acetylsalicylates or substances with a similar activity, especially nonsteroidal anti-inflammatory drugs.
- Active or previous recurrent peptic ulcer and/or gastric/intestinal bleeding, or other types of bleeding such as cerebrovascular hemorrhage.
- Bleeding diathesis; coagulation disorders such as hemophilia and thrombocytopenia.
- Severe hepatic impairment.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.